Exhibit 99.1 Globus Medical Reports First Quarter 2025 Results AUDUBON, PA, May 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine business," commented Dan Sca ...

Core Insights - Globus Medical reported a net sales of $598.1 million for Q1 2025, reflecting a decrease of 1.4% compared to Q1 2024, with U.S. sales slightly increasing by 0.2% while international sales decreased by 7.7% [2][9][42] - The company achieved a GAAP net income of $75.5 million, a significant improvement from a loss of $7.1 million in the same period last year, with diluted EPS rising to $0.54 from a loss of $0.05 [3][9][18] - The company reaffirmed its full-year 2025 revenue guidance in the range of $2.80 to $2.90 billion, while adjusting its non-GAAP diluted EPS guidance down to $3.00 to $3.30 from a previous range of $3.10 to $3.40 [5] Financial Performance - The decrease in worldwide net sales was primarily attributed to fewer enabling technology unit sales, with international net sales decreasing by 4.6% on a constant currency basis [2][9][42] - Non-GAAP diluted EPS for Q1 2025 was reported at $0.68, an increase of 8.5% from $0.63 in Q1 2024 [3][9][38] - The company generated a record free cash flow of $141.2 million for the quarter, with net cash provided by operating activities amounting to $177.3 million [4][40] Debt and Cash Management - Globus Medical returned to a debt-free status by paying off the remaining $450 million of debt from the NuVasive merger [2][4] - As of March 31, 2025, the company had cash and cash equivalents of $461.3 million, down from $784.4 million at the end of 2024 [20][28] Product Performance - The musculoskeletal solutions segment generated $575.9 million in sales, while enabling technologies sales were $22.2 million, down from $32.0 million in the previous year [25][9] - The company continues to focus on innovation and investment in advanced products to enhance patient care [2][5]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Globus Medical, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.74 per share, reflecting a +2.8% change year-over-year, with revenues projected at $628.32 million, up 3.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Globus Medical is higher than the consensus estimate, resulting in a positive Earnings ESP of +2.40%, indicating a bullish sentiment among analysts [10]. Historical Performance - Globus Medical has a strong track record, having beaten consensus EPS estimates in the last four quarters, including a +10.53% surprise in the most recent quarter [12][13]. Stock Ranking - The company currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Conclusion - Globus Medical is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

Core Insights - The first-quarter reporting cycle shows a positive trend with most companies exceeding earnings estimates, although macroeconomic uncertainty is affecting future earnings outlooks [1] - The Medical sector is experiencing significant earnings growth, acting as a buffer against rising market volatility due to increasing tariffs [1][2] Medical Sector Performance - Key medical product companies are recovering from previous cost increases and supply-chain disruptions, with artificial intelligence integration expected to drive medical device adoption in 2025 [2] - At-home medical solutions are projected to continue their growth trend in 2025, despite potential negative impacts from rising tariffs [2] - As of April 30, 45% of Medical sector companies reported quarterly earnings, with 85.2% beating earnings estimates and 70.4% exceeding revenue expectations [3] - Year-over-year earnings in the Medical sector improved by 60.5%, while revenues increased by 7.8% [3] Earnings Expectations - The Medical sector's first-quarter earnings are anticipated to surge by 40%, with sales expected to rise by 8.3% year over year [4] - Hims & Hers Health is projected to report a first-quarter EPS of 14 cents, indicating a 180% growth from the previous year [8] - Globus Medical's first-quarter EPS is estimated at 74 cents, reflecting a 2.8% increase from the prior year [10] - QuidelOrtho's first-quarter EPS is expected to be 60 cents, showing a 36.4% improvement from the year-ago period [11] - Haemonetics is anticipated to report a first-quarter EPS of $1.22, suggesting a 35.6% increase from the previous year [12]

Core Viewpoint - Globus Medical, Inc. will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025, after market close [1] Financial Results Announcement - The financial results will be available on the Globus Medical website [1] - A teleconference will be held at 4:30 p.m. Eastern Time to discuss the performance with the investment community [2] - Participants can access the conference call live via webcast on the Investors page of the Globus Medical website [2] Teleconference Participation - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [3] - The audio archive of the call will be available on the Investors page after the event [3] Company Overview - Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs [4] - The company emphasizes innovation, education, clinical support, and advancements in various medical fields including spine, orthopedic trauma, and joint reconstruction [4]

Company Overview - Globus Medical, Inc. (GMED) has completed the acquisition of Nevro Corp., enhancing its position in the musculoskeletal market [1] - The acquisition is expected to unlock a market opportunity valued at $2.50 billion [4] Financial Performance - Globus Medical has a market capitalization of $9.47 billion, with projected revenues for 2025 expected to increase by 6.5% year over year [3] - Following the acquisition, net sales projections for 2025 are estimated to be between $2.80 billion and $2.90 billion, an increase from previous estimates of $2.66 billion to $2.69 billion [6] Market Trends - The global orthopedic devices market was valued at $59.4 billion in 2023, with a projected compound annual growth rate of 5.3% through 2032, driven by factors such as the rising prevalence of osteoporosis and musculoskeletal diseases [7] Recent Developments - Globus Medical recently launched the COHERE ALIF Spacer, a new product designed for anterior lumbar interbody fusion surgery, along with Modulus ALIF Blades, expanding its product offerings [9] Stock Performance - Since the acquisition announcement on April 3, shares of Globus Medical have decreased by 4.6%, closing at $72.02 [2] - Over the past year, GMED shares have increased by 29.5%, contrasting with an 18.8% decline in the industry [10]

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to ...

Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from adverse macroeconomic events and intense competition rema ...

Core Viewpoint - Globus Medical (GMED) is experiencing growth in demand for its Musculoskeletal Solutions products, but faces challenges from a difficult macroeconomic environment, leading to a current Zacks Rank of 3 (Hold) [1] Factors Driving GMED's Shares - The company is gaining market share in musculoskeletal solutions, driven by strong performance in implantable devices, biologics, accessories, and unique surgical instruments [2] - Notable growth in product categories includes expandables, biologics, minimally invasive surgery (MIS) screws, 3D printed implants, and cervical offerings [2] - In Q4, musculoskeletal sales improved by 4.5% year over year, with a significant contribution from international spine business and a 43.5% increase in global Enabling Technologies revenues [3] - The acquisition of Nevro Corporation is expected to add an additional $2 billion market space to GMED's reach in the musculoskeletal market [3] Product Launches and R&D - In Q4 2024, GMED launched five new products, including the QUARTEX MIS system and the ALLEGIANCE Retractor System, aimed at enhancing surgical procedures [4] - The company anticipates a strong pipeline of product launches in 2025, with R&D expenses projected to increase by 11.2% [5] Business Integration and Synergies - GMED's merger with NuVasive has created a global musculoskeletal company focused on innovation and addressing clinical needs, enhancing customer reach and surgeon relationships [6] - Integration with NuVasive is progressing well, exceeding collaboration targets and accelerating value creation and shareholder returns [7] Market Performance and Competitive Landscape - Over the past three months, GMED shares have declined by 12%, compared to a 3.8% decline in the industry, but the company is expected to regain momentum through strategic market expansion and new product launches [8] - The musculoskeletal devices market is highly competitive, with major players like Zimmer Biomet, Stryker, and Johnson & Johnson's DePuy, necessitating continuous product innovation and acquisitions for GMED to maintain market share [10] Economic Challenges - GMED is facing negative trends in the global economy, including interest rate fluctuations and inflation, which have led to an 88.9% increase in the cost of goods sold and a 52.5% rise in SG&A expenses in 2024 [9]

Core Viewpoint - Globus Medical, Inc. has launched two new products, the COHERE™ ALIF Spacer and Modulus™ ALIF Blades, aimed at enhancing surgical efficiency and patient outcomes in anterior spine surgery [1][3][4] Product Launches - The COHERE™ ALIF Spacer features proprietary porous surface technology that promotes bone in-growth while retaining the imaging and mechanical properties of solid PEEK interbody spacers [1][3] - Modulus™ ALIF Blades provide surgeons with various fixation options using the same interbody spacer, improving procedural efficiency by reducing the number of surgical steps and instruments required [1][2] Clinical Benefits - The integration of Porous PEEK technology in the COHERE™ ALIF Spacer is expected to enhance clinical outcomes for anterior cervical fusion and lumbar spine surgery, with significant benefits in radiographic assessment of fusion [1][3] - The Modulus™ ALIF Blades are designed to minimize complications by reducing instrument passes near major vessels, thus allowing for a more minimally invasive surgical approach [2][3] Commitment to Innovation - Globus Medical emphasizes its dedication to advancing surgical outcomes and providing best-in-class solutions tailored to varying patient anatomies and surgeon preferences [4] - The company aims to address unmet clinical needs through continuous innovation in product development [4][5]